Kazia Therapeutics is a clinical-stage oncology company developing therapies for aggressive solid tumors. The company aims to move beyond conventional cancer pathway inhibition by using precision approaches designed to reprogram tumor biology, restore anti-tumor immunity, and address treatment resistance, metastasis, and recurrence. Its portfolio includes clinical and preclinical development programs spanning several therapeutic technologies.

Paxalisib is an oral, once-daily, brain-penetrant small molecule that inhibits both PI3K and mTOR, pathways involved in tumor growth and survival. Kazia is also advancing a PD-L1 Protein Degrader Platform, including lead asset NDL2, designed to selectively target tumor-associated nuclear forms of PD-L1. Its SETDB1 Inhibitor Platform includes MSETC, a lead asset intended to target disease-associated SETDB1 complexes linked to immune evasion, resistance, and metastasis. Across these programs, the company seeks to influence not only tumor signaling but also epigenetic regulation and the immune microenvironment. Kazia reports clinical trials and research activity across oncology indications, including brain and breast cancers, and shares pipeline updates, scientific publications, and investor information through its website.